A generic version of Absorica® (isotretinoin capsules) has been made available by Teva Pharmaceuticals.

Isotretinoin capsules are indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5mm or greater.  The generic product is available 6 dosage strengths: 10mg, 20mg, 25mg, 30mg, 35mg, and 40mg.

Due to the potential for significant adverse reactions, the product is only available through a restricted program (iPLEDGE® REMS) and is reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics.

Reference


Continue Reading

Teva announces the launch of the first generic version of Absorica® (isotretinoin) capsules, for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older, in the United States. [press release]. Tel Aviv, Israel and Parsipanny, NJ; Teva Pharmaceuticals: April 29, 2021.